ClinicalTrials.gg
Active, not recruitingNCT03642964Updated Jul 11, 2024

A Study in Patients With Major Depressive Disorder

A Phase 2 interventional study of CTC-501 in Major Depressive Disorder (MDD), sponsored by Chase Therapeutics Corporation. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Chase Therapeutics Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
1,027th of 1,323
24 · median 70
Started
2018
with 49 others
Phase 2
271 of 1,500
45 open now
Primary completion
2025-12
later than 12 of 258 live
Registered
946th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 1,027th largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 50 that started in 2018, is one of 271 in phase 2, reaches primary completion later than 12 of the 258 other live ones, and was the 946th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).

Read the detailed description

This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).

Subjects will sign consent form prior to any study related procedure and will complete screening assessments. Subjects will be randomized to either the treatment group or the placebo group at a ratio of 1:1.

The study will be conducted in two parts. Titration period On Day 1, subjects will complete all baseline assessments prior to the 1st dosing.

Pramipexole group: Consenting individuals meeting accession criteria will start pramipexole 2.0mg daily dose (1.0mg twice a day) with ondansetron 16mg daily dose (8mg twice a day). Pramipexole will be titrated up daily or every two days depends on each patients' tolerability up to the first intolerable dose (FID) or maximum allowed dose (5 mg/day) according to titration schedule (Table 1). Once subjects reach their FID, their maximum allowed dose (MTD) will be defined as 1 mg below their FID.

During titration, subjects will be admitted to the clinic (subjects will be discharged on the day following their pramipexole FID or Day 8 if subjects reach to 5 mg/day of pramipexole.

Placebo group will take 3 placebo tablets twice a day. Maintenance period During the maintenance phase, patients will be treated with pramipexole MTD or MAD with ondansetron 16mg/day for the remainder of the 8-week treatment.

Placebo group is taking 3 tablets of placebo twice a day during the trial. Exit visit After the Week 8 visit, study medications will be discontinued, and subject will return for Exit visit at Week 9.

After the Exit visit, all subjects will return to their prior treatment for depression or started on a new therapeutic regimen as medically appropriate.

At study completion (or at other times in accordance with Stopping Rules given below), and all study participants will return to their pre-admission therapeutic regimen or started on a new therapeutic regimen as medically appropriate. Higher doses of pramipexole IR may be tapered off at rates deemed medically appropriate by PI.

In this modified single blind study, efficacy raters will be kept unaware of the participants' treatment status.

An independent data and safety monitoring board (DSMB) will be appointed to have responsibility for safeguarding the interests of the trial subjects and assessing the safety and tolerability of the study treatments during the trial.

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patient Population: Males and females with a diagnosis of major depressive disorder

Inclusion Criteria:

  1. Signed an Institutional Review Board (IRB) approved document indicating that they understand the purpose of and procedures required by the study and are willing to participate in the study and comply with all study procedures and restrictions. Informed consent must be obtained from the patient and/or a designated representative prior to initiating screening procedures to evaluate eligibility of the study.
  2. Males and females aged 18 and 65 years inclusive.
  3. Meet R criteria for major depression, single episode or recurrent episode, with or without melancholia and without psychotic features (296.21, 296.22, 296.23, 296.31, 296.32, or 296.33).
  4. Had a total score of > 18 on the HAM-D (17-item version), and a score of > 2 on the depressed mood item of the HAM-D at the screening visit and at the baseline visit.
  5. Patients who are currently not on any antidepressants or, Patients on antidepressants and agree to the appropriate (certain antidepressants with prolonged effects (e.g., fluoxetine) may need longer than 2 weeks post-discontinuation to obtain relatively uncontaminated baseline evaluation).
  6. Agreed not to start psychotherapy or behavior therapy during the trial. Patients currently on these types of therapy for at least 3 months are eligible for the study and could continue to receive therapy during the trial.

Exclusion Criteria:

  1. Women who are pregnant, or lactating; or taking a low-estrogen "mini-pill" .
  2. Individuals who are currently taking either study medication (pramipexole and/or ondansetron).
  3. Renal and hepatic dysfunction with:

    • Total : >1.5 x UNL
    • : >2.5 x UNL
    • ALT: >2.5 x UNL
    • Serum Creatinine: >1.5 x UNL
    • : \<30 mL/min (calculated by Cockcroft and Gault equation)
  4. to any component of either study medication.
  5. Lifetime history of hypomania/mania, psychotic disorder, dementia and borderline or antisocial personality disorders.
  6. History of a serious suicidal attempt in the past 12 months; presence of serious suicidal tendencies/potential; modified C-SSRS >4.
  7. Positive urine screen for benzodiazepines, cocaine/cocaine metabolites, cannabinoids, amphetamines, barbiturates, and opiates or history of moderate or severe substance dependence (drugs or alcohol, DSM-V-R criteria) within the past 6 months of the screening visit.
  8. Non-responders to at least two trials of antidepressant treatment in the past. (Therapeutic dose for at least 6 weeks)
  9. Patients currently taking or have taken the following medications within the past 6 months.

    • Centrally acting dopamine antagonists
    • MAOI
  10. Patients considered unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator.
  11. Patients who have clinical significant hypotension or any clinical significant abnormality at screening.
  12. Any other acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives.
  13. Patients who have participated in another clinical trial with an drug within previous 30 days or 5 half-lives whichever is longer.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    treatment

    CTC-501 (pramipexole IR, given with ondansetron) given orally twice daily

    Drug: CTC-501

  • Placebo comparator
    placebo

    generic placebo tablets given orally twice daily

    Drug: CTC-501

Interventions

  • pramipexole IR, given with ondansetron

06

What researchers measure

Primary outcomes

  1. Tolerability will be assessed by the determination of a Maximum Tolerated Dose of pramipexole

    All subjects will be assessed for dose limiting side effects such as nausea, vomiting and diarrhea.

    Time frame: multiple over 8 weeks

Secondary outcomes

  1. Safety will be assessed by Incidence of Treatment-Emergent Adverse Events

    Incidence and nature of adverse events; vital signs; weight ; physical examination changes; clinical laboratory evaluations; ECG.

    Time frame: Multiple over 8 weeks

  2. The Montgomery-Åsberg Depression Rating Scale

    Change from baseline in the following depression scale; The Montgomery-Åsberg Depression Rating Scale (abbreviated MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorder. Mean change from baseline on the Montgomery Asberg Depression Rating Scale. (MADRS) Relative to Standard of Care. The MADRS is a 10 item scale with each item scored from 0 to 6 where 0 represents minimal symptoms and 6 represents maximum response to that item. The total MADRS score ranges from 0 to 60.

    Time frame: Multiple over 7 weeks

  3. Clinical Global Impression - Severity scale

    Change from baseline in the following depression scales.Mean change from baseline on the CGI-Severity of Illness(CGI-SI) score overtime.The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. o CGI-Global Improvement (CGI-GI) score at the end of 8-week maintenance period

    Time frame: Multiple over 7 weeks

  4. Clinical Global Impression - Improvement scale

    Change from baseline in the following depression scales;The Clinical Global Improvement - CGI-Global Improvement (CGI-GI) score at the end of 8-week maintenance period is a one question scale comparing who the clinician feels the patient's condition has changed from baseline. The scale is from 0-7 (0 being 'not assessed' to 7 being 'very much worse'.

    Time frame: at week 8 only

  5. Pharmacokinetics will measure plasma concentrations of pramipexole and ondansetron

    Plasma concentrations of pramipexole and ondansetron will be measured at various times throughout the study in only pramipexole group. Both groups will have blood draws.

    Time frame: Multiple over 7 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — At this time there is no plan to share IPD.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Dec 2025, 87 months after the start.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 87 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2018
First posted
Aug 22, 2018
StartActual
Sep 10, 2018
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03642964
Lead sponsor
Chase Therapeutics Corporation
Responsible party
Sponsor
First posted
Aug 22, 2018
Start date
Sep 10, 2018
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jul 11, 2024

Study contacts

Mark Leibowitz, MD
principal investigator · Collaborative Neuroscience Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion